NCT00943319View on ClinicalTrials.gov

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2018

Conditions
LeukemiaLymphomaMyeloma
Interventions
DRUG

Busulfan

Daily intravenous dosing to target AVC

DRUG

Fludarabine

Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.

DRUG

Campath

All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).

PROCEDURE

Stem Cell Transplant

Infusion of bone marrow and donors(related/ unrelated).

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00943319 - Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter